Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

20 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study.
Rambaldi A, Iurlo A, Vannucchi AM, Noble R, von Bubnoff N, Guarini A, Martino B, Pezzutto A, Carli G, De Muro M, Luciani S, McMullin MF, Cambier N, Marolleau JP, Mesa RA, Tibes R, Pancrazzi A, Gesullo F, Bettica P, Manzoni S, Di Tollo S. Rambaldi A, et al. Among authors: gesullo f. Leukemia. 2020 Aug;34(8):2234-2237. doi: 10.1038/s41375-020-0735-y. Epub 2020 Feb 11. Leukemia. 2020. PMID: 32047238 Free PMC article. Clinical Trial. No abstract available.
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea.
Pacilli A, Rotunno G, Mannarelli C, Fanelli T, Pancrazzi A, Contini E, Mannelli F, Gesullo F, Bartalucci N, Fattori GC, Paoli C, Vannucchi AM, Guglielmelli P. Pacilli A, et al. Among authors: gesullo f. Blood Cancer J. 2018 Nov 22;8(12):122. doi: 10.1038/s41408-018-0152-x. Blood Cancer J. 2018. PMID: 30467377 Free PMC article.
Validation of the Mayo alliance prognostic system for mastocytosis.
Mannelli F, Gesullo F, Rotunno G, Pacilli A, Pieri L, Guglielmelli P, Vannucchi AM. Mannelli F, et al. Among authors: gesullo f. Blood Cancer J. 2019 Feb 11;9(2):18. doi: 10.1038/s41408-019-0179-7. Blood Cancer J. 2019. PMID: 30741929 Free PMC article. No abstract available.
Spectrum of ASXL1 mutations in primary myelofibrosis: prognostic impact of the ASXL1 p.G646Wfs*12 mutation.
Rotunno G, Mannarelli C, Brogi G, Pacilli A, Gesullo F, Mannelli F, Fiaccabrino S, Sordi B, Paoli C, Marone I, Rumi E, Manfredini R, Barosi G, Cazzola M, Vannucchi AM, Guglielmelli P. Rotunno G, et al. Among authors: gesullo f. Blood. 2019 Jun 27;133(26):2802-2808. doi: 10.1182/blood.2018879536. Epub 2019 May 10. Blood. 2019. PMID: 31076447 Free article. No abstract available.
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease.
Loscocco GG, Mannelli F, Mannelli L, Vergoni F, Gesullo F, Rotunno G, Guglielmelli P, Vannucchi AM. Loscocco GG, et al. Among authors: gesullo f. Am J Hematol. 2020 Dec;95(12):1622-1624. doi: 10.1002/ajh.25806. Epub 2020 Apr 17. Am J Hematol. 2020. PMID: 32242958 Free article. No abstract available.
Gene expression profile correlates with molecular and clinical features in patients with myelofibrosis.
Rontauroli S, Castellano S, Guglielmelli P, Zini R, Bianchi E, Genovese E, Carretta C, Parenti S, Fantini S, Mallia S, Tavernari L, Sartini S, Mirabile M, Mannarelli C, Gesullo F, Pacilli A, Pietra D, Rumi E, Salmoiraghi S, Mora B, Villani L, Grilli A, Rosti V, Barosi G, Passamonti F, Rambaldi A, Malcovati L, Cazzola M, Bicciato S, Tagliafico E, Vannucchi AM, Manfredini R. Rontauroli S, et al. Among authors: gesullo f. Blood Adv. 2021 Mar 9;5(5):1452-1462. doi: 10.1182/bloodadvances.2020003614. Blood Adv. 2021. PMID: 33666652 Free PMC article.
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients.
Loscocco GG, Guglielmelli P, Gangat N, Rossi E, Mannarelli C, Betti S, Maccari C, Ramundo F, Jadoon Y, Gesullo F, Ceglie S, Paoli C, Pardanani A, De Stefano V, Tefferi A, Vannucchi AM. Loscocco GG, et al. Among authors: gesullo f. Am J Hematol. 2021 Nov 1;96(11):1472-1480. doi: 10.1002/ajh.26332. Epub 2021 Sep 6. Am J Hematol. 2021. PMID: 34424575 Free PMC article.
Increased Plasma Levels of lncRNAs LINC01268, GAS5 and MALAT1 Correlate with Negative Prognostic Factors in Myelofibrosis.
Fantini S, Rontauroli S, Sartini S, Mirabile M, Bianchi E, Badii F, Maccaferri M, Guglielmelli P, Ottone T, Palmieri R, Genovese E, Carretta C, Parenti S, Mallia S, Tavernari L, Salvadori C, Gesullo F, Maccari C, Zizza M, Grande A, Salmoiraghi S, Mora B, Potenza L, Rosti V, Passamonti F, Rambaldi A, Voso MT, Mecucci C, Tagliafico E, Luppi M, Vannucchi AM, Manfredini R. Fantini S, et al. Among authors: gesullo f. Cancers (Basel). 2021 Sep 22;13(19):4744. doi: 10.3390/cancers13194744. Cancers (Basel). 2021. PMID: 34638230 Free PMC article.
The prognostic contribution of CBL, NRAS, KRAS, RUNX1, and TP53 mutations to mutation-enhanced international prognostic score systems (MIPSS70/plus/plus v2.0) for primary myelofibrosis.
Loscocco GG, Rotunno G, Mannelli F, Coltro G, Gesullo F, Pancani F, Signori L, Maccari C, Esposito M, Paoli C, Vannucchi AM, Guglielmelli P. Loscocco GG, et al. Among authors: gesullo f. Am J Hematol. 2024 Jan;99(1):68-78. doi: 10.1002/ajh.27136. Epub 2023 Oct 17. Am J Hematol. 2024. PMID: 37846894
Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes.
Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, Patriarca A, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM. Barbui T, et al. Among authors: gesullo f. Ann Hematol. 2024 Feb;103(2):437-442. doi: 10.1007/s00277-023-05577-9. Epub 2023 Dec 7. Ann Hematol. 2024. PMID: 38060001 Clinical Trial.
20 results